PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.\', \'Department of Ophthalmology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.\', \'Institute of Molecular Medicine and Experimental Immunology, University Clinic of Rheinische Friedrich-Wilhelms-University, Bonn, Germany.\', \'Department of Oncology, Wuhan Pulmonary Hospital, Wuhan, Hubei, China.\', \'Department of Oncology, The First College of Clinical Medical Science, Yichang, Hubei, China.\', \'Department of Oncology, Jingzhou Central Hospital, Jingzhou, Hubei, China.\', \'Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, Idaho State University, Meridian, Idaho, USA.\', \'Institute of Molecular Medicine and Experimental Immunology, University Clinic of Rheinische Friedrich-Wilhelms-University, Bonn, Germany xlyuan1020@163.com ckurts@uni-bonn.de.\', \'Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China xlyuan1020@163.com ckurts@uni-bonn.de.\']
?:citedBy
  • -1
?:creator
?:doi
  • e00415710.1136/jitc-2021-004157
?:doi
?:hasPublicationType
?:journal
  • Journal for immunotherapy of cancer
is ?:pmid of
?:pmid
?:pmid
  • 35264438
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.798
?:rankingScore_hIndex
  • 26
?:title
  • Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all